MetLife, Inc.

MetLife, Inc. (MET) Market Cap

MetLife, Inc. has a market capitalization of $54.36B.

Price: $84.49

1.03 (1.23%)

Market Cap: 54.36B

NYSE · time unavailable

CEO: Michel Abbas Khalaf

Sector: Financial Services

Industry: Insurance - Life

IPO Date: 2000-04-05

Website: https://www.metlife.com

MetLife, Inc. (MET) - Company Information

Market Cap: 54.36B|Sector: Financial Services

Company Profile

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.

Analyst Sentiment

76%
Strong Buy

From 18 Active Polls

1Y Forecast: $94.29

▲ +11.6% Potential Upside

Consensus Target Metrics

Low Bound

$86

Median

$95

High Bound

$102

Average

$94

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$94.29
▲ +11.60% Upside
Low Target
$86.00
2% Risk
Median Target
$95.00
12% Mid
High Target
$102.00
21% Max
Consensus
Buy
25 / 33 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)54,36446,10952,49254,75153,94654,78256,99457,67849,650
Enterprise Value ($M)51,96843,71350,64354,35051,67452,68555,64154,75847,226
Price to Earnings Ratio (P/E)15.229.7316.2215.2818.5014.4911.2110.7413.12
Price/Earnings-to-Growth Ratio (PEG)0.3914.452.331.31
Price to Sales Ratio (P/S)0.712.422.203.243.143.003.093.152.84
Price to Book Ratio (P/B)2.021.691.851.891.951.992.081.871.82
Price to Free Cash Flow Ratio (P/FCF)3.2917.166.4915.3524.6712.8511.1113.8414.23
Enterprise Value to Sales (EV/Sales)2.292.133.223.012.883.022.992.70
Enterprise Value to EBITDA (EV/EBITDA)8.8424.6736.7036.7041.3732.6833.9324.3332.37
Debt to Equity Ratio-0.410.740.710.690.720.700.680.610.67

MET Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$84.49
Intrinsic Value$266.49
Market Alignment
Undervalued by 215.4%relative to calculated intrinsic value
9.00%
Exp: 5%5%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$12.04B
Perpetuity TV Value$226.51B
Discounted TV (PV)$95.68B
TV Weighting %59.5%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 METLIFE INC (MET) — Investment Overview

🧩 Business Model Overview

MetLife is a global insurance and retirement company that pools long-dated policyholder premiums and invests them in high-quality assets to fund future claims and benefits. The value chain is centered on (1) underwriting and pricing (life, disability, and other protection products), (2) policy administration and customer servicing, (3) asset management of the general account and separate account business, and (4) distribution through employer relationships, independent advisors, and institutional partners.

The core economic linkage is spread and fee generation: premiums and other cash flows fund investments; the difference between investment returns and the cost of liabilities (claims, benefits, and operating costs) becomes a key driver of earnings. For savings/retirement products (including many annuity formats), MetLife also earns recurring contract charges and other fees tied to policy assets, creating durability to earnings when account balances remain in force.

💰 Revenue Streams & Monetisation Model

  • Insurance premiums and related charges: Primarily recurring over the life of policies, with earnings shaped by mortality/morbidity, lapse behavior, and reserve adequacy.
  • Net investment income (general account): Monetisation of capital gathered from policyholders; largely reflects asset yield, credit performance, and hedging/ALM discipline versus the economic cost of liabilities.
  • Fee income (asset-based businesses): Ongoing charges associated with policy account values and distribution/service economics; less dependent on underwriting risk and more tied to persistence and market value trends.
  • Policyholder account movement mechanics: For variable and index-linked products, investment performance can impact fee bases and hedging outcomes, while preserving a recurring fee component versus pure premium models.

Margin drivers are therefore structural: (i) the level and stability of policy inflows/persistence, (ii) investment spread and risk-adjusted returns after hedging, (iii) operating expense efficiency, and (iv) capital intensity moderated by reserving and regulatory capital management.

🧠 Competitive Advantages & Market Positioning

Primary moat: Regulatory and capital framework combined with credit/underwriting culture. In insurance, competitors cannot freely scale without maintaining strong capital positions, disciplined reserving, and risk controls that satisfy regulators. This creates an enduring barrier to entry and to rapid share gains, even when distribution is available.

Secondary moat: Cost of deposits / “float-like” economics and persistence of in-force business. Insurance liabilities are not equivalent to demand deposits, but the long-duration nature of many MetLife contracts provides a valuable funding base. When priced and managed well, the liability structure supports investment deployment and earnings stability through cycles.

Competitive benchmarking (industry focus vs peers):

  • Prudential Financial (PRU): Strong emphasis on U.S. life/annuity and sizable international operations. Versus MetLife, the overlap is meaningful in U.S. retirement and protection, but MetLife’s scale and product mix reflect a different balance between protection and retirement-heavy exposures.
  • Manulife Financial (MFC): Notable international footprint with growing emphasis on retirement and wealth. Compared with Manulife, MetLife’s positioning is more centered on U.S. insurance and retirement distribution economics.
  • AIG (AIG): Broader insurance footprint with significant life/retirement and property/casualty capabilities. AIG’s mix can shift perceived risk profiles more toward underwriting cycles outside pure life/retirement versus MetLife’s focus.

Across these competitors, the shared challenge is earning risk-adjusted returns while meeting capital and reserving requirements. The differentiator is execution consistency—pricing discipline, ALM/hedging rigor, and reserve adequacy—rather than product novelty.

🚀 Multi-Year Growth Drivers

  • Demographic tailwinds for protection and retirement: Aging populations and wealth transfer support long-duration demand for life insurance and annuity/retirement solutions.
  • Retirement savings penetration and product adoption: Over a multi-year horizon, increased coverage gaps and the need for income solutions support growth of annuity and employer/individual retirement channels.
  • Distribution leverage and persistence: Durable relationships with advisors, employers, and institutional partners support policy inflow and lower lapse volatility when servicing and product suitability remain strong.
  • Improving risk-adjusted earnings through ALM and portfolio construction: Consistent hedging frameworks and disciplined credit selection can translate market opportunities into steadier spread outcomes.
  • Scale efficiencies: Insurance administration, underwriting workflows, and investment operations can benefit from scale, supporting operating leverage even when top-line growth normalizes.

⚠ Risk Factors to Monitor

  • Interest rate and duration risk (ALM mismatch): Changes in yield curves can affect the economic value of liabilities and the reinvestment yield on assets, impacting spreads.
  • Credit risk and spread volatility: Investment portfolio performance depends on issuer credit quality, default risk, and the pace of credit normalization in stressed environments.
  • Reserve adequacy and model risk: Life and annuity liabilities rely on actuarial assumptions (mortality, lapse, behavior, expenses). Errors can surface through unfavorable experience.
  • Regulatory and capital regime changes: Capital requirements, reserving rules, and solvency frameworks can alter the rate at which earnings can be distributed and reinvested.
  • Persistency and lapse risk: Policyholder behavior can shift with product economics, competitive offers, and macro conditions.
  • Operational, technology, and cyber risk: Large legacy and digital systems increase exposure to operational disruptions and data security failures.

📊 Valuation & Market View

Insurance equities are typically valued using price-to-book and earnings multiple frameworks that emphasize return on equity, durability of earnings, and capital strength. Key valuation sensitivity usually comes from:

  • Quality of earnings: Spread sustainability, underwriting results, and reserve development.
  • Capital generation and deployment: Ability to compound book value while maintaining solvency targets.
  • Interest rate and credit assumptions: Market expectations for reinvestment, hedging costs, and credit losses.
  • Growth versus risk trade-offs: Whether growth is achieved through favorable business mix and pricing discipline.

In this sector, headline growth can matter less than whether incremental capital earns competitive risk-adjusted returns without stressing reserves or capital ratios.

🔍 Investment Takeaway

MetLife’s long-term investment appeal rests on structural advantages common to high-quality life/retirement insurers: a durable policyholder funding base, recurring fee and premium economics, and—most importantly—regulatory-capital constraints that reinforce underwriting and risk-management discipline. The strongest case is built on consistent execution in ALM, credit selection, and reserving, enabling compounding of capital while supporting protection and retirement demand over a full cycle.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MET.

seekingalpha.com2026-06-05

Dividend Champion, Contender, And Challenger Highlights: Week Of June 7

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

gurufocus.com2026-06-04

MetLife Inc (MET) Shares Surge 3.1% -- What GF Score of 77 Tells Investors

On June 04, 2026, MetLife Inc (MET) shares rose 3.1% to a current price of $83.46. This shift places the stock within a 52-week range of $67.33 to $85.29, refle

businesswire.com2026-06-03

MetLife CFO to Speak at Morgan Stanley US Financials Conference

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that John McCallion, executive vice president and CFO, and head of MetLife Investment Management, will participate in a fireside chat at the Morgan Stanley US Financials Conference on Wednesday, June 10, 2026, at 1:00 pm ET. The live webcast can be listened to by clicking here. Please visit the link at least 15 minutes in advance to allow time to register or sign in. If you miss the remarks, you can access a replay at the abov.

zacks.com2026-06-03

Here's Why Investors Should Stay Neutral on MetLife Stock for Now

MET is backed by premium growth, AI-driven efficiency and strong liquidity, but volatile investment income and lower ROIC support a neutral view.

gurufocus.com2026-05-31

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where

gurufocus.com2026-05-29

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR

gurufocus.com2026-05-29

Ares Marks Eagle Football Debt To 16 Cents As MetLife Pushes Back

Ares Management (ARES) and MetLife (MET) are now facing off in a high-stakes restructuring fight around Eagle Football, the football ownership group tied to clu

businesswire.com2026-05-28

MetLife Expands Guaranteed Retirement Income Offering with Innovative Flexible Annuity Option

NEW YORK--(BUSINESS WIRE)-- #401k--As demand for guaranteed lifetime income grows, MetLife today introduced a new liquidity feature for its immediate income annuity, the MetLife Guaranteed Income Program (MGIP). This innovative design offers defined contribution plan participants a simple way to convert savings into reliable income while maintaining greater flexibility early in retirement. The Annuity Cancellation Option gives participants the freedom to cancel their annuity within the first three year.

seekingalpha.com2026-05-24

MetLife: Time To Go Long The Common Shares And 6.35% Yielding Preferreds

MetLife delivers robust adjusted income, supporting a bullish stance on common shares and fixed-rate preferreds. MET's preferred dividend payout ratio remains low, with $24.5B in common equity providing strong downside protection for preferred holders. Series A floating-rate preferreds yield 5.45%-5.5%, attractive if short-term rates rise, but fixed-rate Series F offers a higher current yield.

businesswire.com2026-05-15

MetLife Declares Second Quarter 2026 Preferred Stock Dividends

NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.31190376 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: MET PRA). Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary s.

zacks.com2026-05-14

These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

businesswire.com2026-05-12

MetLife and Global Citizen Launch “Footwork for Futures” Social Media Challenge to Help Expand Access to Education and Sports

NEW YORK--(BUSINESS WIRE)--Today, MetLife and Global Citizen announced Footwork for Futures, a global soccer-themed social media challenge that supports children's access to quality education and sports to foster more confident and resilient communities.

marketbeat.com2026-05-11

MetLife Q1 Earnings Call Highlights

MetLife NYSE: MET reported a strong start to 2026, with executives telling analysts that first-quarter results reflected broad-based growth across its operating businesses, favorable underwriting trends and disciplined capital management under its New Frontier strategy.

zacks.com2026-05-07

MET Tops Q1 EPS Estimates on Strong Investment Income and Volume Growth

MetLife posts a Q1 earnings beat as investment income, underwriting gains and strong segment growth lift profits and revenues.

seekingalpha.com2026-05-07

MetLife, Inc. (MET) Q1 2026 Earnings Call Transcript

MetLife, Inc. (MET) Q1 2026 Earnings Call Transcript

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Most recent quarter (2026-03-31): Revenue $19.07B and Net Income $1.19B, translating to EPS of $1.75. YoY (vs. 2025-03-31): Revenue +4.5% (from $18.26B to $19.07B) and Net Income +25.3% (from $945M to $1.19B). QoQ (vs. 2025-12-31): Revenue -19.8% and Net Income +46.3% (from $809M to $1.19B). Profitability improved across the period: net margin rose to 6.2% from 5.2% YoY, and operating margin increased to 7.9% from 7.4% YoY; QoQ profitability also strengthened materially (net margin up from 3.4% in Q4). The company remains well supported by liquidity and balance sheet resilience: cash and short-term investments of $338.8B and net debt is negative (net cash position of about $2.4B), indicating strong ability to fund operations and shareholder returns. Operating cash flow was $2.69B in the quarter, with free cash flow of the same amount; capital intensity appears minimal in the provided data. Total shareholder return appears modest based on the supplied performance (price +8.9% over 1Y) and the indicated dividend yield (~0.10%): capital appreciation is the dominant component, with buybacks present (repurchased ~$755M of common stock in Q1)."

Revenue Growth

Neutral

YoY revenue growth is positive (+4.5%), but QoQ revenue fell sharply (-19.8%), suggesting seasonality or mix shift rather than sustained acceleration.

Profitability

Good

Net income grew faster than revenue YoY (+25.3%). Margins expanded: net margin rose to 6.2% from 5.2% YoY; operating margin improved to 7.9% from 7.4% YoY. QoQ net margin also jumped (3.4% to 6.2%).

Cash Flow Quality

Neutral

Operating cash flow and free cash flow both were $2.69B in Q1. Dividends paid were small ($45M) relative to earnings, and buybacks occurred (-$755M), supporting shareholder returns without stressing cash generation.

Leverage & Balance Sheet

Good

Liquidity is strong with cash and short-term investments of ~$338.8B. Balance sheet shows net cash (net debt about -$2.4B). Equity remains stable at ~$27.8B total equity.

Shareholder Returns

Positive

1Y price change is +8.9% (no >20% momentum boost). Dividend yield is very low (~0.10%), but buybacks are present; total return appears driven primarily by capital appreciation plus modest distributions.

Analyst Sentiment & Valuation

Neutral

With current price ~$78.08 and consensus target ~$97 (upside ~24%), valuation appears supportive, though the score is tempered by volatility in QoQ revenue.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Met delivered a strong Q1 2026 start with adjusted EPS of $2.42 (+23% YoY) and adjusted earnings of $1.6B (+18% YoY), backed by broad-based top-line growth and resilient margins. Expense discipline was a key tell: the direct expense ratio fell to 11.9%, beating the 2026 annual target by ~20 bps, while absorbing ~50 bps from PineBridge integration. Investment results were supported by above-expectation VII, with private equity returning ~2.9% and VII contributing ~24 bps to RIS spreads, keeping VII effectively flat. RIS spreads still showed sequencing headwinds: core ex-VII fell to 95 bps (down ~4 bps), attributed to rotation of large Q4 PRT inflows, though management expects 2Q improvement. Management addressed working-age mortality sustainability with research on potential drivers and framed any pricing normalization as gradual. Japan faced an industry regulatory matter, but management maintained it hasn’t impacted Met’s sales/results in the quarter.

AI IconGrowth Catalysts

  • Group Benefits: total sales +15% YoY and adjusted PFOs excluding participating contracts +4%
  • Japan: sales +26% YoY (constant currency strength) with Japan A&H sales +77% YoY on a new product and life growth driven by yen variable and USD single premium products
  • Korea/Asia: Korea sales +44% YoY (constant currency) supported by product expansion and rising equity markets
  • Latin America: sales +20% YoY (constant currency) with adjusted PFOs +25% (+11% constant currency) supported by Brazil, Mexico, Chile growth
  • RIS: adjusted earnings +11% YoY supported by higher VII and favorable underwriting; PRT/annuity and reinsurance sales breadth including U.K.-funded reinsurance and retail annuity reinsurance

Business Development

  • PineBridge acquisition integration cited as driving MIM earnings +68% and expense margin benefits
  • Private equity secondary activity: divested ~ $750M of private equity assets (mark-to-market/secondary structure enabling continued management by MIM)
  • PRT mandates and longevity reinsurance referenced as major flow sources impacting RIS spread/rotations

AI IconFinancial Highlights

  • Adjusted earnings: $1.6B or $2.42/share, +18% YoY (EPS +23%)
  • Adjusted premiums/fees/other revenue (ex pension risk transfers): +10% YoY
  • Variable investment income: $518M pretax; third consecutive quarter above-expectation VII with private equity return ~2.9%
  • Adjusted ROE: 17%, top end of 15%–17% target range
  • Direct expense ratio: 11.9% vs 12.1% 2026 annual target (ahead by 20 bps); management absorbed ~50 bps impact from PineBridge while still ahead
  • Group Benefits: adjusted earnings $439M (+19% YoY); Group Life mortality ratio 80.1% vs 2026 target range 83%–88%
  • Group Benefits nonmedical health interest adjusted benefit ratio: 75.8% vs annual target 70%–75%
  • RIS: adjusted earnings $451M (+11% YoY); RIS full-year adjusted earnings outlook reiterated at $1.6B–$1.8B
  • RIS investment spread: total 119 bps, down ~5 bps sequentially; VII contributed ~24 bps (flat vs prior) and core spread ex VII 95 bps
  • Effective tax rate on adjusted earnings: 24% (bottom of 24%–26% guidance range)
  • Corporate & Other adjusted loss: ($177M) vs ($129M) prior year, driven by foregone earnings from prior-year strategic reinsurance and lower recurring interest margins

AI IconCapital Funding

  • Returned ~$1.1B to shareholders in the quarter: ~$750M share repurchases + ~$370M dividends
  • Additional repurchase: ~$200M net common shares in April
  • Remaining authorization: $1.1B
  • Subordinated debt issued: $1.0B; offering oversubscribed >5x and issued at tight relative spreads
  • Holding company cash/liquid assets: $3.9B (top end of $3B–$4B liquidity buffer)

AI IconStrategy & Ops

  • New Frontier: described as entering Year 2 with an emphasis on acceleration and execution across diversified businesses
  • AI/technology: invested >$3.2B over 5 years to simplify/modernize ecosystem; AI deployment described as reducing complexity/costs and improving direct expense ratio
  • PineBridge integration: first fully integrated quarter post-acquisition; institutional outflows partly stabilized into April
  • Ukraine divestiture decision: business divested with new regional parent positioning for continued growth

AI IconMarket Outlook

  • RIS full-year adjusted earnings outlook: $1.6B–$1.8B maintained
  • RIS spread outlook framework: 2Q expected improvement from lower asset rotations, while yield curve described as persistently flat with the short end higher than earlier expectations
  • Japan solvency outlook: initial economic solvency ratio (ESR) expected in the middle of 170%–190% target range after regulatory filings in June

AI IconRisks & Headwinds

  • Working-age mortality favorability: management cited ~2 points favorable prior-quarter development plus ~0.5 point severity fluctuation; discussed potential drivers (COVID pull-forward, GLP-1) and indicated any pricing flowback would occur gradually over years
  • Japan regulatory matter (industry-wide): management states comprehensive review completed, seconded employees returned, practice discontinued; regulators communications ongoing and details confidential; management asserted no impact on sales/results in the quarter
  • RIS spread pressure: core spread ex VII down ~4 bps sequentially attributed to Q4 inflow rotation from PRT mandates; expectations for some 2Q improvement but persists in flat yield curve environment
  • MIM flows: institutional outflows ~$2B in quarter due to market volatility and integration-related platform bringing together; stabilization noted in latter Q1 and April, but ongoing execution risk remains

Q&A: Analyst Interest

  • Topic: Sustainability of working-age mortality favorability (COVID/GLP-1 risk to underwriting trend): Management attributed Q1 results to ~2 points favorable prior-quarter development plus ~0.5 point severity fluctuation, noted favorable working-age trends in CDC data, and said drivers are being researched (including COVID pull-forward and GLP-1). If persists, some pricing catch-up would occur gradually over years, not quarters.
  • Topic: Japan regulatory actions and potential franchise impact: Management emphasized this is an industry-wide issue, confirms comprehensive internal review completion, seconded employees returned, and the practice discontinued. Corrective actions were posted on their website. Management stated conversations with the FSA continue; press referenced a reporting order, but details remain confidential, and they reported no observable impact to Met’s results/sales.
  • Topic: RIS spread trajectory amid flat yield curve and VII contribution: Management said Q1 total RIS spread was 119 bps, down ~5 bps sequentially; VII contributed ~24 bps, making ex-VII core spread 95 bps, with the sequential decline largely in line with February expectations tied to rotating large Q4 PRT inflows. They expect 2Q improvement from lower rotations, but noted persistently flat yield curve dynamics.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the MET Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for MET.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (MET)

© 2026 Stock Market Info — MetLife, Inc. (MET) Financial Profile